BEAT Stock Risk & Deep Value Analysis
Heartbeam Inc
Healthcare • Health Information Services
DVR Score
out of 10
What You Need to Know About BEAT Stock
We analyzed Heartbeam Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BEAT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
BEAT Risk Analysis & Red Flags
What Could Go Wrong
The company could exhaust its current cash runway of approximately 3.75 quarters (approximately $13.5M cash with a $3.6M quarterly burn) before generating meaningful revenue from its limited commercial launch or securing further non-dilutive financing. This would necessitate additional, highly dilutive equity offerings or even bankruptcy, significantly jeopardizing shareholder value due to the explicitly flagged going concern risks.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Zero revenue reported in Q1 2026, despite prior regulatory clearances and a stated 'limited commercial launch'.
- ⚠
Explicit 'going concern' risk flagged, indicating fundamental doubts about the company's ability to continue operations, even after a recent $11.5M equity offering.
- ⚠
High quarterly cash burn of $3.6 million against a cash balance of $2.0 million (pre-financing) and a current ~$13.5M (post-financing), implying a short runway without revenue.
- ⚠
Significant shareholder dilution from the recent $11.5M equity offering, without commensurate revenue growth to offset value reduction per share.
Upcoming Risk Events
- 📅
Q2 2026 Earnings (Estimated early-August 2026): Continued $0 revenue and a cash burn exceeding $4M could erode investor confidence and trigger further stock decline.
- 📅
Failure to Secure Additional Funding (Q1 2027): With a current runway of ~3.75 quarters, if the company doesn't secure significant non-dilutive financing or substantial revenue by early 2027, it faces severe liquidity crisis.
When to Reconsider
- 🚪
Exit if quarterly revenue (Q2 2026 or Q3 2026) remains at $0, indicating a complete failure of initial commercialization efforts.
- 🚪
Sell if total cash and cash equivalents fall below $5.0 million (post the $11.5M raise), signaling a dangerously short cash runway.
- 🚪
Exit if management announces another significant dilutive equity offering (e.g., >$10M) within the next 6-9 months without substantial revenue growth.
Unlock BEAT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Heartbeam Inc (BEAT) Do?
Market Cap
$50.14M
Sector
Healthcare
Industry
Health Information Services
Employees
16
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Visit Heartbeam Inc WebsiteInvestment Thesis
If Heartbeam can successfully scale its limited commercial launch of the FDA-cleared AIMIGo, secure additional FDA clearances for its extended-wear patch and heart attack detection products within the next 12-18 months, and demonstrate a clear path to $20-30M in annual recurring revenue by FY2028 while managing its cash burn effectively, then the market could re-rate the company to a $200-$300M valuation (4-6x P/S on projected revenue), representing a 4-6x return on its current $0.05B market cap. This is bullish because the underlying 3D VECG technology offers a differentiated approach to a large and critical healthcare market, and the current valuation heavily discounts its future success, effectively pricing in substantial failure.
Is BEAT Stock Undervalued?
Unlock the full AI analysis for BEAT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
BEAT Price Targets & Strategy
12-Month Target
$2.50
Bull Case
$5.00
Bear Case
$0.50
Valuation Basis
Speculative, based on a market re-rating for initial commercialization success and extended operational runway, assuming $5M+ annualized revenue run-rate by early FY2027 and reduced dilution risk. At $2.50, implies ~180% upside from current price, still a fractional market cap of long-term potential.
Entry Strategy
Highly speculative, consider dollar-cost averaging on dips to $0.70 - $0.85 (testing prior lows/support) given the volatile nature and high risk.
Exit Strategy
Profit-taking at $2.50-$3.00 if significant commercial traction is demonstrated; Stop loss at $0.60 if cash burn accelerates without revenue, or if further dilutive financing is announced prematurely.
Portfolio Allocation
1-3% for aggressive risk tolerance only, as this is a highly speculative, binary outcome investment.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is BEAT Financially Healthy?
Valuation
P/E Ratio
-1.64
Forward P/E
2.64
PEG Ratio
-0.16
Price/Book
131.10
Profitability
Return on Equity
-571.06%
EPS
$-0.63
Balance Sheet
Current Ratio
1.45
Quick Ratio
1.35
Cash & Equivalents
$2.00M
Cash Flow
Operating Cash Flow
-$3.60M
Other
Beta (Volatility)
-0.66
Does BEAT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is nascent, primarily stemming from patented technology and FDA clearances. Its durability will depend on continued innovation, successful commercialization, and the ability to fend off larger competitors with greater R&D and distribution resources. Without widespread adoption and strong brand recognition, this moat remains fragile.
Moat Erosion Risks
- •Competitors developing functionally equivalent or superior technologies, potentially bypassing Heartbeam's patent protections or offering more comprehensive solutions.
- •Lack of rapid market adoption of 3D VECG technology, making it difficult to establish a dominant position before competitors catch up.
- •Failure to secure further FDA clearances for pipeline products (extended-wear patch, heart attack detection) or delays in market entry.
BEAT Competitive Moat Analysis
Sign up to see competitive advantages
BEAT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (due to penny stock status, dilution, and lack of revenue, despite potential technology)
Institutional Sentiment
Neutral (No analyst coverage or significant institutional activity identified in provided research, likely due to small market cap and early stage)
Insider Activity (Form 4)
No specific Form 4 filings for CEO/CFO buying or selling were provided in the last 90 days. However, the recent $11.5 million equity offering implies management's facilitation of significant dilution.
Options Flow
Normal options activity (given no specific data provided, default to normal)
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 results)
Surprise Probability
Low for revenue (likely $0 or minimal), Medium for EPS (potential for beat by expense control, as seen in Q1 2026)
Historical Earnings Pattern
Insufficient data to establish a consistent pattern, but given its early stage and zero revenue, any positive commercial or regulatory news could trigger a volatile rally, while continued negative financials could lead to sell-offs.
Key Metrics to Watch
Competitive Position
Top Competitor
iRhythm Technologies (IRTC) - Market leader in long-term cardiac monitoring patches (Zio XT), demonstrating successful commercialization and recurring revenue model, albeit for a slightly different application.
Market Share Trend
Nascent; currently attempting to gain initial market share in specific acute cardiac monitoring segments with AIMIGo.
Valuation vs Peers
Not meaningful to compare traditional valuation multiples (P/E, P/S) to established peers given Heartbeam's $0 revenue. It trades as a speculative R&D-stage company.
Competitive Advantages
- •Proprietary 3D Vector Electrocardiography (VECG) technology for improved diagnostic accuracy.
- •FDA-cleared AIMIGo for certain acute cardiac events, providing a regulatory head start for this specific application.
- •Focus on acute and specific diagnostic challenges where current ECG may be insufficient.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive BEAT Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings (Estimated early-August 2026): Key focus on updates regarding the limited commercial launch for arrhythmia assessment and management's guidance on revenue and cash burn. Any positive revenue figures would be significant.
- •Update on Extended-Wear Patch & Heart Attack Detection (Q3/Q4 2026): Progress on clinical trials or regulatory submissions for these pipeline products could signal broader market opportunity.
Medium-Term (6-18 months)
- •FDA Clearance for Extended-Wear Patch (Q4 2026 / Q1 2027): Successful regulatory clearance would open a significant new revenue stream beyond AIMIGo, targeting a large segment of the cardiac monitoring market.
- •Initial Revenue Generation from Commercial Launch (Q4 2026 / Q1 2027): Reporting even minimal but growing revenue (e.g., $0.5M-$1M) from AIMIGo's limited commercial rollout would validate market adoption and execution.
Long-Term (18+ months)
- •Widespread Adoption of 3D VECG Technology (2027-2028): If Heartbeam's differentiated technology becomes a standard for specific acute cardiac events, leading to $50M+ annual recurring revenue by FY2029.
- •Strategic Partnerships for Distribution (2028+): Securing a major distribution partner (e.g., large medical device company) for AIMIGo and pipeline products, expanding market reach and reducing sales costs, potentially leading to a $250M+ market capitalization.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for BEAT?
- ✓
Watch quarterly reported revenue (any figure >$0 indicates initial commercial traction).
- ✓
Monitor cash burn rate (should ideally decrease or stabilize below $3M per quarter as revenue scales).
- ✓
Track progress on FDA submissions and clearances for new devices (e.g., extended-wear patch).
- ✓
Monitor news for any major distribution partnership announcements.
Bull Case Analysis
Sign up free to see the bull case
Competing with BEAT
See how Heartbeam Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Heartbeam Inc BEAT | $50.1M | 3.9 | -1.6 | — | — | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Heartbeam Inc Makes Money
Heartbeam Inc. is a medical technology company focused on developing and commercializing non-invasive, AI-driven cardiac diagnostic solutions. Its core offering, AIMIGo, utilizes proprietary 3D vector electrocardiography (VECG) to provide more precise and rapid detection of acute coronary events and arrhythmia assessment than traditional ECGs. The company aims to generate revenue by selling or licensing its FDA-cleared devices and potentially offering associated subscription services to healthcare providers, enabling improved remote patient monitoring and more accurate diagnoses in clinical and emergency settings for cardiovascular conditions.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Heartbeam Inc (BEAT)?
As of May 21, 2026, Heartbeam Inc has a DVR Score of 3.9 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Heartbeam Inc?
Heartbeam Inc's market capitalization is approximately $50.1M. The company operates in the Healthcare sector within the Health Information Services industry.
What ticker symbol does Heartbeam Inc use?
BEAT is the ticker symbol for Heartbeam Inc. The company trades on the NCM.
What is the risk level for BEAT stock?
Our analysis rates Heartbeam Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of BEAT?
Heartbeam Inc currently has a price-to-earnings (P/E) ratio of -1.6. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the BEAT DVR analysis updated?
Our AI-powered analysis of Heartbeam Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BEAT (Heartbeam Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.